Summary

Aprogenex, Inc. ("Aprogenex" or the "Company") is engaged in the commercialization of diagnostic and therapeutic technologies. The Company, through its diagnostic operations, develops, manufactures and intends to market diagnostic test systems based on its proprietary DNA probe technology to identify the presence or extent of genetic abnormalities and disease. The Company's Rapid Intact Gene Hybridization Technology ("RIGHTechnology") utilizes the Company's synthetically manufactured probes and proprietary "cocktail" reagent solution which allows analysis of single intact cells at a molecular level. The Company is also engaged in the expansion of its...